Bellus Health Inc. is working on drug candidate BLU-5937 that targets chronic cough. On June 20, drug giant Merck & Co. gave a presentation on its competing chronic-cough drug candidate and suggested there could be other applications for it targeting other ailments including endometrial pain and sleep apnea. Investors liked the implications for Bellus and pushed the stock higher. A company director was also buying. Between June 20-21, Franklin Berger bought 100,000 shares in the public market between the prices of $2.70 and $2.80.
Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.
Chart reflects public-market transactions of common shares or unit trusts by company officers and directors.